Pasar al contenido principal

MECANISMOS MOLECULARES Y METABOLICOS SUBYACENTES A LA DISFUNCION MITOCONDRIAL

PID2019-110766GA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic remodeling in astrocytes: Paving the path to brain tumor development

  • Jaraíz-Rodríguez, Myriam
  • del Prado, Lucia
  • Balsa, Eduardo
The brain is a highly metabolic organ, composed of multiple cell classes, that controls crucial functions of the body. Although neurons have traditionally been the main protagonist, astrocytes have gained significant attention over the last decade. In this regard, astrocytes are a type of glial cells that have recently emerged as critical regulators of central nervous system (CNS) function and play a significant role in maintaining brain energy metabolism. However, in certain scenarios, astrocyte behavior can go awry, which poses a significant threat to brain integrity and function. This is definitively the case for mutations that turn normal astrocytes and astrocytic precursors into gliomas, an aggressive type of brain tumor. In addition, healthy astrocytes can interact with tumor cells, becoming part of the tumor microenvironment and influencing disease progression. In this review, we discuss the recent evidence suggesting that disturbed metabolism in astrocytes can contribute to the development and progression of fatal human diseases such as cancer. Emphasis is placed on detailing the molecular bases and metabolic pathways of this disease and highlighting unique metabolic vulnerabilities that can potentially be exploited to develop successful therapeutic opportunities., This work was supported by grants to Dr. Balsa from the Spanish Government, Ministerio de Ciencia e Innovación (PID2019-110766GA-I00), European Union's Horizon 2020 research and innovation program (ERC-2020-STG-948478) and Fundación CRIS contra el cancer (PR_EX_2022-01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Compensatory activity of the PC-ME1 metabolic axis underlies differential sensitivity to mitochondrial complex I inhibition

  • Del Prado, Lucia
  • Jaraíz-Rodríguez, Myriam
  • Agro, Mauro
  • Zamora-Dorta, Marcos
  • Azpiazu, Natalia
  • Calleja, Manuel
  • Lopez-Manzaneda, Mario
  • de Juan-Sanz, Jaime
  • Fernández-Rodrigo, Alba
  • Esteban, José A
  • Girona, Mònica
  • Quintana, Albert
  • Balsa, Eduardo
Deficiencies in the electron transport chain (ETC) lead to mitochondrial diseases. While mutations are distributed across the organism, cell and tissue sensitivity to ETC disruption varies, and the molecular mechanisms underlying this variability remain poorly understood. Here we show that, upon ETC inhibition, a non-canonical tricarboxylic acid (TCA) cycle upregulates to maintain malate levels and concomitant production of NADPH. Our findings indicate that the adverse effects observed upon CI inhibition primarily stem from reduced NADPH levels, rather than ATP depletion. Furthermore, we find that Pyruvate carboxylase (PC) and ME1, the key mediators orchestrating this metabolic reprogramming, are selectively expressed in astrocytes compared to neurons and underlie their differential sensitivity to ETC inhibition. Augmenting ME1 levels in the brain alleviates neuroinflammation and corrects motor function and coordination in a preclinical mouse model of CI deficiency. These studies may explain why different brain cells vary in their sensitivity to ETC inhibition, which could impact mitochondrial disease management., This work was supported by grants to E.B. from the Spanish Government, Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (PID2019-110766GA-I00 and PID2022-137404OB-I00), European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation (ERC-2020-STG grant agreement n° 948478) and Fundación CRIS contra el cancer (PR_EX_2022-01). A.Q. was supported by grant PID2020-114977RB-I00 funded by MICIU/AEI /10.13039/501100011033. M.Z. was supported in part by an FPI-UAM PhD fellowship
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Time-resolved mitochondrial screen identifies regulatory components of oxidative metabolism

  • Zamora-Dorta, Marcos
  • Laine-Menéndez, Sara
  • Abia, David
  • González-García, Pilar
  • López, Luis C.
  • Fernández-Montes, Paula
  • Calvo, Enrique
  • Vázquez, Jesús
  • Enríquez, José Antonio
  • Balsa, Eduardo
Defects in mitochondrial oxidative metabolism underlie many genetic disorders with limited treatment options. The incomplete annotation of mitochondrial proteins highlights the need for a comprehensive gene inventory, particularly for Oxidative Phosphorylation (OXPHOS). To address this, we developed a CRISPR/Cas9 loss-of-function library targeting nuclear-encoded mitochondrial genes and conducted galactose-based screenings to identify novel regulators of mitochondrial function. Our study generates a gene catalog essential for mitochondrial metabolism and maps a dynamic network of mitochondrial pathways, focusing on OXPHOS complexes. Computational analysis identifies RTN4IP1 and ECHS1 as key OXPHOS genes linked to mitochondrial diseases in humans. RTN4IP1 is found to be crucial for mitochondrial respiration, with complexome profiling revealing its role as an assembly factor required for the complete assembly of complex I. Furthermore, we discovered that ECHS1 controls oxidative metabolism independently of its canonical function in fatty acid oxidation. Its deletion impairs branched-chain amino acids (BCAA) catabolism, disrupting lipoic acid-dependent enzymes such as pyruvate dehydrogenase (PDH). This deleterious phenotype can be rescued by restricting valine intake or catabolism in ECHS1-deficient cells., This work was supported by grants to Dr. Balsa from the Spanish Government, Ministerio de Ciencia e Innovación (PID2019-110766GA-I00 and PID2022-137404OB-I00), European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation (ERC-2020-STG grant agreement n° 948478), and Fundación CRIS contra el cancer (PR_EX_2022-01). The CBM is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, and is a Severo Ochoa Center of Excellence (grant CEX2021-001154-S) funded by MICIN/AEI/10.13039/501100011033. MZD was supported in part by an FPI-UAM PhD fellowship. SLM was supported in part by a Margarita Salas-UAM postdoctoral fellowship (CA4/RSUE/2022-00037). JAE is supported by PID2021-1279880B funded by MICINN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/Plan de Recuperación Transformación y Resiliencia -PRTR; “la Caixa” Banking Foundation (project LCF/PR/H23/52430010) and CIBERFES (CB16/10/00282) funded by ISCIII. PFM is supported by FPU21/06416 by a fellowship. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MICINN), and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033).